Genes in Human Brain Ischemia
Genes in Human Brain Ischemia
批准号:
8139019
负责人:
W ANDREW KOFKE
金额:
$23.52万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-15 至 2014-02-28
关键词:
AcuteAffectAlzheimer&aposs DiseaseApolipoprotein EBiochemical MarkersBiological MarkersBloodBrainBrain InjuriesBrain IschemiaCalpainCandidate Disease GeneCause of DeathCerebral IschemiaCerebrumClinicalCombination Drug TherapyDevelopmentEnrollmentEnvironmentExerciseFunctional disorderGenesGenetic PolymorphismGenomicsGenotypeGoalsHeart ArrestHeat shock proteinsHumanIschemiaIschemic Brain InjuryKnowledgeLeadModalityN-terminalNeurofilament-HNeurologicOperating RoomsOperative Surgical ProceduresOutcomePathway interactionsPatientsPerfusionPeroxidasesPharmacotherapyPhysiologyProteinsRelative (related person)ReportingResearchResistanceRiskRoleSeminalStereotypingStrokeSyndromeTestingTherapeuticTherapeutic StudiesTherapy Clinical TrialsUnited StatesVariantVenousWeightWorkalpha Spectrinaortic archbasedesigndisabilitygene discoverygene therapyhigh riskimprovednerve injuryneuroprotectionneurotoxicitynovelprogramspublic health relevance
中文摘要
描述(申请人提供):脑缺血后的脑损伤仍然是一个临床挑战,已被证明对大多数已在人类身上测试的治疗方法具有抗药性。拟议研究的总体目标是为随后的单基因和多方面基因和药物疗法的开发寻找最合适的基因。研究在深低温停循环(DHCA)和不完全逆行脑灌注(RCP)的主动脉弓手术中遭受常规缺血挑战的患者;我们的具体目标是检验以下假设:H1。与神经保护、神经毒性和阿尔茨海默病相关的候选基因的多态将预测脑缺血后的损伤程度。三种基于病理生理学的载脂蛋白E(ApoE)、热休克蛋白(HSP)和髓过氧化物酶(MPO),均已有证据表明对脑缺血易感性有影响,将评估三种基于病理生理学的载脂蛋白E(ApoE)、热休克蛋白(HSP)和髓过氧化物酶(MPO)对体外循环断流术后急性神经损伤的六个定量指标(S-1002、NSE、高磷神经丝H、低磷神经丝H、去磷神经丝H和钙痛衍生的α-血影蛋白N端片段)的贡献。H2。在脑缺血损伤的病理生理机制中,与大多数已知的主要机制相关的基因的多态性将影响预后。在相关基因发现的练习中,91个基于病理生理学的基因类型将被检查,以寻找可能对急性神经损伤的量化指标(与H1相同的6个生物标记物)的贡献。对于每个特定的目的,急性神经损伤的定量指标将包括已知的脑损伤的生化标记物,这些标记物来自手术后脑流入和RCP流出的血液和静脉血。将有200名深低温心绞痛患者入选。从这一环境中获得的有关基因组脆弱性的信息不仅将导致手术期间对此类患者的管理方法的变化,而且可能更重要的是,将产生将在与全球脑缺血和中风相关的许多非手术环境中使用的信息。由于中风是美国第三大致死原因和第一大致残原因,这项研究的影响可能非常重大,可能导致中风或其他脑缺血综合征的基因或新药或基因疗法。
公共卫生相关性:手术室环境为研究缺血易损性的基因组变异提供了独特的机会,因为或多或少典型的不完全性脑缺血的发生是相当可预见的。从这一环境中获得的关于基因组脆弱性的信息不仅将导致手术期间对此类患者的管理方法的变化,而且可能更重要的是,将产生将在与全球脑缺血和中风相关的许多非手术环境中使用的信息。由于中风是美国第三大致死原因和第一大致残原因,这项研究的影响可能非常重大,可能导致中风或其他脑缺血综合征的基因或新药治疗。
英文摘要
DESCRIPTION (provided by applicant): Brain damage after cerebral ischemia continues to be a clinical challenge that has proven to be resistant to most therapies that have been tested in humans. The overall objective of the proposed research is to discover the most appropriate genes for subsequent development of single and multifacet gene and drug therapies. Studying patients sustaining a stereotypical ischemic challenge during aortic arch surgery with deep hypothermic circulatory arrest (DHCA) and incomplete retrograde cerebral perfusion (RCP); our specific aims are to test the following hypotheses: H1. Polymorphisms in candidate genes associated with neuroprotection, neurotoxicity, and Alzheimer's disease will predict extent of brain injury after ischemia. Three pathophysiologically based genotypes, apolipoprotein E (ApoE), heat shock protein (HSP), and myeloperoxidase(MPO), all with prior evidence of an effect in vulnerability to brain ischemia, will be evaluated for contribution to six quantitative indicators of acute neural injury after DHCA with RCP (S-1002, NSE, hyperphospho-neurofilament H, hypophospho-neurofilament H, dephospho- neurofilament H, and a calpain-derived N-terminal fragment of alpha-spectrin). H2. Polymorphisms in genes associated with most known major mechanisms in the pathophysiology of brain damage after ischemia will affect outcome. In an exercise in relevant gene discovery, 91 pathophysiologically based genotypes will be examined for possible contribution to a quantitative indicator (the same six biomarkers as in H1) of acute neural injury after DHCA with RCP. For each specific aim quantitative indicators of acute neural injury will include the known biochemical markers of brain damage from brain inflow and RCP effluent blood and venous blood after surgery. Two hundred DHCA patients will be enrolled. Information derived from this setting about genomic vulnerability will not only lead to changes in approach to management of such patients during surgery, but also, and perhaps more importantly, will generate information that will be of use in many non- operative settings associated with global brain ischemia and stroke. As stroke is the third leading cause of death and leading cause of disability in the United States, the impact of this research may be very significant, possibly leading to gene or new drug or gene therapy of stroke or other brain ischemia syndromes.
PUBLIC HEALTH RELEVANCE: The operating room environment provides a unique opportunity for study of genomic variation in ischemic vulnerability, as more or less stereotypical incomplete cerebral ischemia occurs fairly predictably. Such information derived from this setting about genomic vulnerability will not only lead to changes in approach to management of such patients during surgery, but also, and perhaps more importantly, will generate information that will be of use in many non-operative settings associated with global brain ischemia and stroke. As stroke is the third leading cause of death and leading cause of disability in the United States, the impact of this research may be very significant, possibly leading to gene or new drug therapy of stroke or other brain ischemia syndromes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prescribed opioid induced brain damage in chronic pain patients
-
批准号:10473879
-
项目类别:
-
资助金额:$20.31万
-
财政年份:2021
-
负责人:W ANDREW KOFKE
-
依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
-
批准号:9222821
-
项目类别:
-
资助金额:$63.54万
-
财政年份:2014
-
负责人:W ANDREW KOFKE
-
依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
-
批准号:9021009
-
项目类别:
-
资助金额:$62.78万
-
财政年份:2014
-
负责人:W ANDREW KOFKE
-
依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
-
批准号:8696339
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2014
-
负责人:W ANDREW KOFKE
-
依托单位:
Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor
-
批准号:9438563
-
项目类别:
-
资助金额:$61.78万
-
财政年份:2014
-
负责人:W ANDREW KOFKE
-
依托单位:
Validation of NIRS CBF with XeCTCBF
-
批准号:8036098
-
项目类别:
-
资助金额:$23.52万
-
财政年份:2010
-
负责人:W ANDREW KOFKE
-
依托单位:
Validation of NIRS CBF with XeCTCBF
-
批准号:7893486
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2010
-
负责人:W ANDREW KOFKE
-
依托单位:
Genes in Human Brain Ischemia
-
批准号:8048271
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2010
-
负责人:W ANDREW KOFKE
-
依托单位:
Exacerbation of Alzheimer's Disease by Nitrous Oxide
-
批准号:6576030
-
项目类别:
-
资助金额:$7.93万
-
财政年份:2003
-
负责人:W ANDREW KOFKE
-
依托单位:
海外基金